Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.01 USD
Change Today 0.00 / 0.00%
Volume 0.0
RAFA On Other Exchanges
As of 8:10 PM 07/9/15 All times are local (Market data is delayed by at least 15 minutes).

rafarma pharmaceuticals inc (RAFA) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/22/14 - $0.15
52 Week Low
03/24/15 - $0.0052
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

rafarma pharmaceuticals inc (RAFA) Related Businessweek News

No Related Businessweek News Found

rafarma pharmaceuticals inc (RAFA) Details

Rafarma Pharmaceuticals, Inc., a multi-product pharmaceutical company, produces and sells drugs, generic antibiotics, and specialty pharmaceuticals in the Russian Federation. It offers cephalosporin-based products, antibiotics of non-ß structure, and anti-cancer drugs in the form of injections, ampulla packaged products, child suspensions, tablets, and capsules. The company also provides drugs for accidental wounds, inflammatory eye diseases, and immunological disorders. Rafarma Pharmaceuticals, Inc. was formerly known as Johnston Acquisition Corp. and changed its name to Rafarma Pharmaceuticals, Inc. in October 2012. The company is based in Sandy, Utah with a manufacturing and distribution facility in the Russian Federation.

rafarma pharmaceuticals inc (RAFA) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

rafarma pharmaceuticals inc (RAFA) Key Developments

Rafarma Pharmaceuticals Inc. Appoints Mr. Bruno Horn as New President and Director

Rafarma Pharmaceuticals Inc. announced appointment of Mr. Bruno Horn as the new President and Director of the company, effective July 15, 2014. Mr. Horn is the founder of his own consultancy based in Switzerland, specializing in steel trading and the pharmaceutical industry.

Rafarma Pharmaceuticals Announces the Complete Restructuring of Existing EUR 90,000,000 Loan with VNeshconombank

Rafarma Pharmaceuticals Inc. announced the complete restructuring of its existing EUR 90,000,000.00 loan with VNeshconombank (VEBank). Terms and conditions of the restructured loan include a 3-year deferment, or holiday, on all principal and interest payments thus greatly enhancing the financial stability of the company.

Rafarma Pharmaceuticals, Inc. Enters New Distribution Agreement with Amber Pharma Distribution Group

Rafarma Pharmaceuticals, Inc. announced it has entered into a new multi-year distribution contract with Amber Pharma Distribution Group.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RAFA:US $0.01 USD 0.00

RAFA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RAFA.
View Industry Companies

Industry Analysis


Industry Average

Valuation RAFA Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RAFARMA PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at